Stock analysts at StockNews.com initiated coverage on shares of Alimera Sciences (NASDAQ:ALIM – Get Free Report) in a research report issued to clients and investors on Monday. The brokerage set a “hold” rating on the biopharmaceutical company’s stock.
Several other analysts have also weighed in on ALIM. Alliance Global Partners reissued a “neutral” rating on shares of Alimera Sciences in a report on Tuesday, June 25th. Maxim Group reaffirmed a “hold” rating on shares of Alimera Sciences in a report on Tuesday, June 25th. Finally, HC Wainwright lowered Alimera Sciences from a “buy” rating to a “neutral” rating and set a $6.00 target price for the company. in a report on Tuesday, June 25th.
Read Our Latest Analysis on Alimera Sciences
Alimera Sciences Stock Performance
Alimera Sciences (NASDAQ:ALIM – Get Free Report) last issued its quarterly earnings data on Tuesday, August 6th. The biopharmaceutical company reported ($0.06) EPS for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.02). Alimera Sciences had a negative return on equity of 33.70% and a negative net margin of 14.74%. The company had revenue of $27.00 million for the quarter, compared to analyst estimates of $25.76 million. Sell-side analysts expect that Alimera Sciences will post -0.13 EPS for the current fiscal year.
Institutional Investors Weigh In On Alimera Sciences
A number of institutional investors have recently added to or reduced their stakes in ALIM. Renaissance Technologies LLC grew its holdings in Alimera Sciences by 3.9% during the 2nd quarter. Renaissance Technologies LLC now owns 181,694 shares of the biopharmaceutical company’s stock worth $1,010,000 after acquiring an additional 6,900 shares during the period. Rhumbline Advisers acquired a new stake in Alimera Sciences during the 2nd quarter worth $113,000. Fifth Lane Capital LP acquired a new stake in Alimera Sciences during the 1st quarter worth $83,000. Hillsdale Investment Management Inc. acquired a new stake in Alimera Sciences during the 1st quarter worth $169,000. Finally, Bank of New York Mellon Corp acquired a new stake in Alimera Sciences during the 2nd quarter worth $344,000. 99.83% of the stock is owned by institutional investors and hedge funds.
Alimera Sciences Company Profile
Alimera Sciences, Inc, a pharmaceutical company, develops and commercializes prescription ophthalmic retinal pharmaceuticals. It operates through United States, International, and Operating Cost segments. The company offers ILUVIEN, a fluocinolone acetonide intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye (NIU-PS).
Further Reading
- Five stocks we like better than Alimera Sciences
- How to Calculate Options Profits
- Simon Property REIT: A Safe Bet for Growth and Steady Dividends
- What is a Death Cross in Stocks?
- CarMax’s Impressive Rally: What Investors Should Watch Next
- 3 Warren Buffett Stocks to Buy Now
- MarketBeat Week in Review – 9/23 – 9/27
Receive News & Ratings for Alimera Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alimera Sciences and related companies with MarketBeat.com's FREE daily email newsletter.